PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för trametinib dimethyl sulfoxide. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

9 hits

Bibliografisk träff 2013-09-12

Targeting the ERK pathway reduces liver metastasis of Smad4-inactivated colorectal cancer.

Ai X, Wu Y, Zhang W, Zhang Z, Jin G, Zhao J, Yu J, Lin Y, Zhang W, Liang H, Datta PK, Zhang M, Zhang B, Chen X.

Cancer Biol Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.4161/cbt.26427

Bibliografisk träff 2013-09-01

Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide.

Hussar DA, Kaminski JL.

J Am Pharm Assoc (2003) · journal article · DOI 10.1331/japha.2013.13533

Bibliografisk träff 2013-08-23

TGF-β1 and TNF-α differentially regulate Twist1 mediated resistance towards BRAF/MEK inhibition in melanoma.

Menon DR, Wels C, Bonyadi Rad E, Joshi S, Knausz H, Lade-Keller J, Brandner JM, Schaider H.

Pigment Cell Melanoma Res · research support, non-u.s. gov't; journal article · DOI 10.1111/pcmr.12139

Bibliografisk träff 2013-02-23

Trametinib (GSK1120212) in the treatment of melanoma.

Salama AK, Kim KB.

Expert Opin Pharmacother · research support, non-u.s. gov't; review; journal article · DOI 10.1517/14656566.2013.770475

Bibliografisk träff 2012-12-17

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD.

J Clin Oncol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1200/jco.2012.43.5966

Bibliografisk träff 2012-04-01

Molecular targeted therapy in acute myeloid leukemia.

Daver N, Cortes J.

Hematology · review; journal article · DOI 10.1179/102453312x13336169155619

Bibliografisk träff 2012-03-02

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.

Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L, Gilmer TM.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-11-0989

Bibliografisk träff 2011-12-14

Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.

Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E, Conway T, Moy C, Laquerre S, Bachman K, Wooster R, Degenhardt Y.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-11-0505

Bibliografisk träff 2011-01-18

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.

Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, Rominger CM, Erskine S, Fisher KE, Yang J, Zappacosta F, Annan R, Sutton D, Laquerre SG.

Clin Cancer Res · journal article · DOI 10.1158/1078-0432.ccr-10-2200